Brief: Ryvu Therapeutics Says Starts Phase II Study Of RVU120 For Myelofibrosis
05/12/2024 06:03
Dec 5 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* FIRST PATIENT DOSED IN PHASE II STUDY OF RVU120 FOR
MYELOFIBROSIS
* RVU120 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH
RUX
Source text: ID:nEM46JXWla
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys